|
Dr. Quart was elected as a director and appointed as our President and CEO in December 2006. From 2002 until December 2006 Dr. Quart was President of Napo Pharmaceuticals Inc. where he was instrumental in bringing the company public on the London Stock Exchange in July 2006. Prior to Napo Dr. Quart was Senior Vice President Pfizer Global Research and Development and the Director of Pfizer's La Jolla Laboratories where he was responsible for approximately 1 000 employees and an annual budget of almost $300 million. Prior to Pfizer's acquisition of the Warner-Lambert Company Dr. Quart was President of Research and Development at Agouron Pharmaceuticals Inc. a division of the Warner-Lambert Company since 1999. Dr. Quart had joined Agouron in 1993 and was instrumental in the development and registration of nelfinavir (Viracept) which went from the lab bench to NDA approval in 38 months. Dr. Quart spent over ten years at Bristol-Myers Squibb in both Clinical Research and Regulatory Affairs prior to Agouron and was actively involved in the development and registration of important drugs for the treatment of HIV and cancer including paclitaxel (Taxol) didanosine (Videx) and stavudine (Zerit). He has a PharmD from University of California San Francisco. | 